Efficacy and safety of Qi-Boosting Toxin-Resolving formulae for breast cancer: a meta-analysis
Conference: BIBE 2019 - The Third International Conference on Biological Information and Biomedical Engineering
06/20/2019 - 06/22/2019 at Hangzhou, China
Proceedings: BIBE 2019
Pages: 6Language: englishTyp: PDF
Personal VDE Members are entitled to a 10% discount on this title
Authors:
Zhou, Liang (Department of Breast Surgery, The First Hospital of Hunan University of Chinese Medicine, Changsha, China)
Liang, Lixin (Departement of Health management, The First Hospital of Hunan University of Chinese Medicine, Changsha, China)
Zeng, Zhijun (Department of Geratic Surgery, Xiangya Hospital, Central South University, Changsha, China)
Gong, Houwu (DHC SOFTWARE CO., Ltd, Beijing, China)
Abstract:
Objective: To systematically evaluate the efficacy and safety of Yiqi Jiedu Decoction in the adjuvant treatment of breast cancer. Methods: PubMed, EMbase, The Cochrane Library, CNKI, WanFang Data, VIP and CBM databases were searched by computer to collect randomized controlled trials (RCTs) of adjuvant therapy with Yiqi Jiedu method for breast cancer from database establishment to March 24, 2019. After the two investigators independently screened the literature, extracted the data and evaluated the risk of bias of the included studies, a meta-analysis was performed using RevMan 5.3 software. Results: A total of 8 RCTs, including 667 patients, were included. Meta-analysis results showed that compared with the control group, adjuvant therapy with Yiqi Jiedu method could improve the effective rate of treatment [OR = 5.50, 95% CI (2.70, 11.24), P < 0.00001] and quality of life [MD = 3.03, 95% CI (2.52, 3.54), P < 0.00001], and could reduce nausea, vomiting and other toxicities [OR = 0.49, 95% CI (0.26, 0.93), P = 0.03]. The differences between the groups were statistically significant. Conclusion: The current evidence shows that Yiqi Jiedu Decoction has a good effect in the treatment of breast cancer, can improve the efficiency of treatment, quality of life, and reduce some of the adverse reactions of chemotherapy. Limited by the number and quality of included studies, the above conclusions need to be verified by more high-quality studies.